NHS saves £25 million from blood glucose meters

A company aimed at improving diabetes care has revealed during Diabetes Week that it has managed to save the NHS more than £25 million.

By supplying cost-effective meters, GlucoRx has managed to save the NHS money and offer diabetic patients a way to measure their blood glucose levels. The company formed in 2010 and its Nexus blood glucose testing system is the second most popular device in the country.

The company spoke about its achievement during Diabetes Week, which is organised by Diabetes UK and has the theme ‘Know Diabetes, Fight Diabetes’.

Chris Chapman, director of GlucoRx said: “As an innovative company we are always looking to push the barriers of science and healthcare and find ways to develop and deliver cost-effective products, which bring benefits to both people with diabetes and the NHS. We pride ourselves on prioritising patient care so profits can go towards extra nurses, newer equipment, greater research and be reinvested into care of the local community.

“Having saved the NHS over £25 million in the past three years the target now is to save the NHS £100 million. We are doing this by reaching out to more Clinical Commissioning Groups and Health Boards, which commission healthcare in the community, across the UK.”

The savings of £25 million were made in the past three years and have been  calculated by using the NHS Prescription Cost Analysis and ePACT, an online application with 60 months of prescription data. The company is now aiming to save the NHS £100 million.

The company continues to work with a number of regional organisations to help raise awareness of diabetes, setting up a number of fundraising events for charities.

 

 



Reece Armstrong is a reporter for Digital Health Age. Coming from the North East of England, Reece has an MA in Media & Journalism and a BA in Popular & Contemporary Music from Newcastle University. Reach him on Twitter or email via: reece.armstrong@rapidnews.com


'NHS saves £25 million from blood glucose meters' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2019 Rapid Life Sciences Ltd, a Rapid News Group Company. All Rights Reserved.

Privacy policy

Terms and conditions